Valeant’s poorly-received quarterly result pushed the stock to the lower-end of my price target ($15.68), established on October 5. The company took a $1B goodwill write-down and missed a few $500 million items. This includes revenue, EBITDA, and the forecast. R&D spend was flat at $100M. The only bright spot did not suggest significant growth: B+L’s sales grew in the single digits.What a Valeant Shareholder has on hand:Tipranks picked up my last write-up on Valeant as a “sell.” The average return on VRX is 28%:Tipranks could not record my notes in the value investing forum on avoiding the stock. VRX is not one of the 3-4 biotech stocks in the ideal top stock holdings. One day it could be, but not this quarter.Other notable calls include Radcom (RDCM), Corning (GLW), Ubiquiti Networks (UBNT). $RDCM, Radcom Ltd. / 60 An update on Valeant is forthcoming. Real-time alert followers will get an email when this is published here. I will update my upside target price (previously at $29 - $32.68).Separately, Endo International (ENDP) reported a robust quarter but guided lower. It cited - you guessed it - generic drug competition has a headwind. Look for pressure rising for PRGO, AGN, and MYL.